The deal was negotiated by the Medicines Patent Pool – a U.N.-led partnership that raises money for AIDS, malaria and tuberculosis. Last year, the U.S. National Institutes of Wellness allowed among its patented medications to be made generically via the same group, but this the 1st cope with a private company. ‘We will continue to work with Gilead and others to increase usage of all people living with HIV in developing countries,’ stated Ellen ‘t Hoen, executive director of the Medicines Patent Pool. Other pharmaceutical companies, including F. Hoffman-La Roche, Sequoia Pharmaceuticals and ViiV Health care, a joint venture between GlaxoSmithKline Pfizer and PLC Inc., are in talks with the U.N.-led group.Early detection allows ophthalmologists to treat individuals before optic nerve harm occurs and would provide us the best chance of protecting their eyesight. A symptomless vision disease like glaucoma highlights the need for regular vision exams. The American Academy of Ophthalmology recommends that everyone possess a complete eye test by an ophthalmologist at age 40 and adhere to the follow-up test schedule recommended by their doctor. This during Glaucoma Consciousness Month January, the Academy encourages people to learn more about the disease known as the sneak thief of sight. Those who have a family history of glaucoma, or who are African-American or Hispanic, could be at higher risk. To find out more on glaucoma, its risk factors and treatment options, visit.

Allos to complete merger with AMAG Pharmaceuticals Allos Therapeutics, Inc.